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Abstract
Background: Kawasaki disease is an acute vasculitis of infants and young children that is recognized through a
constellation of clinical signs that can mimic other benign conditions of childhood. The etiology remains unknown
and there is no specific laboratory-based test to identify patients with Kawasaki disease. Treatment to prevent the
complication of coronary artery aneurysms is most effective if administered early in the course of the illness. We
sought to develop a diagnostic algorithm to help clinicians distinguish Kawasaki disease patients from febrile
controls to allow timely initiation of treatment.
Methods: Urine peptidome profiling and whole blood cell type-specific gene expression analyses were integrated
with clinical multivariate analysis to improve differentiation of Kawasaki disease subjects from febrile controls.
Results: Comparative analyses of multidimensional protein identification using 23 pooled Kawasaki disease and 23
pooled febrile control urine peptide samples revealed 139 candidate markers, of which 13 were confirmed (area
under the receiver operating characteristic curve (ROC AUC 0.919)) in an independent cohort of 30 Kawasaki
disease and 30 febrile control urine peptidomes. Cell type-specific analysis of microarrays (csSAM) on 26 Kawasaki
disease and 13 febrile control whole blood samples revealed a 32-lymphocyte-specific-gene panel (ROC AUC
0.969). The integration of the urine/blood based biomarker panels and a multivariate analysis of 7 clinical
parameters (ROC AUC 0.803) effectively stratified 441 Kawasaki disease and 342 febrile control subjects to diagnose
Kawasaki disease.
Conclusions: A hybrid approach using a multi-step diagnostic algorithm integrating both clinical and molecular
findings was successful in differentiating children with acute Kawasaki disease from febrile controls.
Background
Kawasaki disease (KD) is an acute vasculitis that affects
infants and children and is the leading cause of acquired
pediatric heart disease in the U.S. and Japan [1]. The
cause of KD remains unknown, although epidemiologic
and clinical observations suggest that an infectious
agent(s) may trigger the inflammatory process in geneti-
cally susceptible hosts, who then manifest the clinical
syndrome [2]. The diagnosis of KD is currently based
on clinical signs and supportive non-specific laboratory
testing [3,4]. There is no specific diagnostic test for the
disease. If not diagnosed and treated promptly, patients
with KD may develop coronary artery dilatation or
aneurysms. The cardiovascular damage can be largely
prevented by timely administration of intravenous
immunoglobulin (IVIG). Thus, there is an acute need
for a sensitive and specific diagnostic test or panel that
can facilitate diagnosis and permit timely treatment.
We postulated that specific patterns of blood leuko-
cyte gene expression and plasma or urine protein excre-
tion patterns are associated with KD. Identification of
these biomarkers could provide insight into the patho-
physiology of KD, and even give clues to its etiology.
Investigators have taken both genomic and proteomic
approaches to biomarker discovery in KD.
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Transcriptional profiling of blood leukocytes has identi-
fied disease-specific expression patterns [5-9]. Protein
biomarker studies [7,10-14] have revealed elevated levels
of cytokines, chemokines, and acute phase reactants, but
none are uniquely elevated in KD.
Our previous analysis [8,9] of peripheral whole blood
gene expression compared acute KD and febrile control
(FC) patients, revealing increased relative abundance of
transcripts associated with innate immune and proin-
flammatory responses and decreased abundance of tran-
scripts associated with natural killer cells and CD8+
lymphocytes. Expression analyses of separate blood cell
type would be more informative. However, the isolation
of peripheral blood subsets is cumbersome and may
alter gene expression. We, therefore, compared KD and
FC whole blood gene expression using cell type-specific
significance analysis of microarrays (csSAM [15]) to ana-
lyze differential gene expression for each cell type in a
biological sample based on microarray data and relative
cell-type frequencies.
Urine is a rich source of proteolytically cleaved pro-
teins cleared from plasma by the kidneys. Profiling ana-
lysis of the urinary proteome/peptidome is highly
informative for both uro-genital and systemic disease
classification [16,17]. Using this approach, we previously
described urine peptide biomarkers associated with
renal transplantation rejection [18,19] and systemic juve-
nile idiopathic arthritis (SJIA)[20]. We, therefore, per-
formed mass spectrometric analyses of urinary peptides
in KD and FC patients.
In this study, we applied an ensemble data-mining
approach [21] integrating either blood cell type-specific
gene expression or urine peptidome profiling with clini-
cal multivariate analysis to improve the diagnosis of KD.
Materials and methods
Patient demographics and samples
Informed consent was obtained from the parents of all
subjects and assent from all subjects > 6 years of age.
This study was approved by the human subjects protec-
tion programs at the University of California San Diego
(UCSD) and Stanford University. Inclusion criteria for
KD subjects were based on the American Heart Associa-
tion Guidelines [22]. All KD subjects had fever for at
least three days and four of five classic criteria or three
or fewer criteria with coronary artery abnormalities
documented by echocardiogram. The 441 KD patients
were distributed according to either the IVIG therapy
outcome (Non responder: n = 68; Responder: n = 271;
Late treatment: n = 55; Non treated: n = 16; IVIG +
Remicade for coronary artery aneurysms: n = 10; data
not available: n = 21) or the coronary artery lesion sta-
tus (Normal: n = 323; Aneurysms: n = 34; Dilated: n =
83; Data not available: n = 1). FC subjects were age-
similar children evaluated for fever accompanied by at
least one of the KD criteria (rash, conjunctival injection,
oral mucosa changes, extremity changes, enlarged cervi-
cal lymph node). Febrile children with prominent
respiratory or gastrointestinal symptoms were specifi-
cally excluded such that the majority of the controls had
KD in the differential diagnosis of their condition. All
subjects provided samples of blood and urine and
underwent other diagnostic tests at the discretion of the
managing clinicians. De-identified clinical laboratory test
data were extracted from the UCSD KD electronic data-
base for multivariate analysis. FC patients had a clini-
cally or culture proven etiology for their febrile illnesses
or underwent resolution of fever and clinical signs
within three days of obtaining their clinical samples
(designated as ‘viral syndrome’).
We compiled 3 cohorts of KD and FC subjects evalu-
ated for their febrile illnesses at Rady Children’s Hospi-
tal San Diego (Tables 1, 2 and 3): 783 for clinical score
development (clinical group: 441 KD and 342 FC); 106
for urine peptidome analysis (urine group: 53 KD and
53 FC); and 39 for cell type-specific microarray analysis
of whole blood (blood group: 23 KD and 16 FC). The
blood group (KD n = 23, FC n = 16) is a subset of pre-
viously analyzed samples (NCBI GEO GSE15297 [9],
peripheral whole blood expression analysis) with com-
plete clinical data for all subjects. We chose KD and FC
patients for the urine and blood groups with similar age
and same gender. Patient demographic data were ana-
lyzed using SAS 9.2 (SAS Institute Inc., Cary, NC, USA).
The KD patients in the clinical group were more predo-
minantly male and were younger than the FC patients
but did not differ in ethnicity (Table 1). The 53 KD and
53 FC patients in the urine group were age-matched
and did not differ in gender or ethnicity. Asian ethnicity
Table 1 Demographics of the 783 Patients with Kawasaki
Disease or Febrile Conditions
Kawasaki Disease Febrile Condition P-
value
n = 441 (56.3%) n = 342 (43.7%)
Age (months)a 35.6 [1.0, 178.0, 29.7-
33.9]
44.0 [1.0, 210.0, 39.0-
45.3]
0.002
Male 273 (61.9%) 190 (55.6%) 0.002
Ethnicity
Asian 59 (13.5%) 31 (9.1%) 0.116
African
American
17 (3.9%) 12 (3.5%)
Caucasian 117 (26.7%) 87 (25.5%)
Hispanic 149 (34.0%) 129 (37.8%)
Mixed 90 (20.6%) 69 (20.2%)
aReported as means with minimum, maximum, and 95% confidence interval
in bracket. T-test was used.
All other variables were reported as the number of patients and were
analyzed using Fisher’s Exact test.
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was more common among KD subjects in the blood
group.
KD clinical score calculation
We used linear discriminant analysis (LDA) to stratify
individual subjects based on a series of clinical explora-
tory variables. R http://www.r-project.org/ library MASS
function ‘lda’ was utilized. Coefficients of linear discri-
minants (LD1) were calculated as a measure of the asso-
ciation of each variable with the final diagnosis. The
discriminant score was calculated from the seven vari-
ables (Figure 1) with the largest (absolute value) coeffi-
cients. All patients were stratified into subgroups with
low (5% likelihood KD), intermediate, and high (95%
likelihood KD) clinical scores.
Microarray analysis of peripheral whole blood
We performed csSAM [15] to analyze differential gene
expression for each blood cell type in our previous KD
array data set (NCBI GEO GSE15297 [9]). Our expres-
sion analysis de-convoluted the major blood cell types:
lymphocytes, neutrophils, immature neutrophils (band
forms), monocytes, and eosinophils. For each gene, in
each cell type, we calculated the contrast in its de-con-
voluted expression between KD and FC groups. The
false discovery rate (FDR) was calculated as the ratio of
genes whose differentiation exceeded a given threshold
in the real dataset compared with the number of genes
found significant by multiple permutations of the
samples.
Urine collection, storage and processing
Urine samples (5-10 mL) were either spontaneously
voided or collected by bladder catheterization and held
at 4°C for up to 48 hours before centrifugation (2,000 g
× 20 minutes at room temperature) and freezing of the
supernatant at -70°C. The details of urine processing,
preparation of peptides, extraction and fractionation are
reported elsewhere [17].
Urine peptidomic data analysis
We pooled equal peptide content from 23 KD and 23 FC
(Additional file 1, Supplementary Table 3) and subjected
the pooled peptidome samples to multi-dimensional pro-
tein identification technology (MUDPIT: strong cation
exchange (SCX) and reverse phase (RP) separations) analy-
sis using Fourier transform ion cyclotron resonance (FT
ICR) mass spectrometry. The mass spectrometer’s data-
dependent acquisition isolates peptides as they elute and
subjects them to Collision-Induced Dissociation, recording
Table 2 Demographics of the 106 Patients with Urine Peptidome Data
Kawasaki Disease Febrile Condition P-value
n = 53 (5.0%) n = 53 (50.0%)
Age (months)a 50.6 [3.0, 182.0, 33.6-49.8] 54.2 [5.0, 209.0, 39.9-58.8] 0.670
Male 36 (67.9%) 33 (62.3%) 0.409
Ethnicity
Asian 7 (13.4%) 6 (11.3%) 0.095
African American 1 (1.9%) 1 (1.9%)
Caucasian 10 (19.2%) 12 (22.6%)
Hispanic 18 (34.6%) 16 (30.2%)
Mixed 16 (30.8%) 11 (20.8%)
aReported as means with minimum, maximum, and 95% confidence interval in bracket. T-test was used.
All other variables were reported as the number of patients and were analyzed using Fisher’s Exact test.
Table 3 Demographics of the 39 Patients with Microarray Data
Kawasaki Disease Febrile Condition P-value
n = 23 (59.0%) n = 16 (41.0%)
Age (months)a 43.2 [5.0, 152.0, 27.1-49.6] 64.3 [6.0, 188.0, 38.1-90.6] 0.125
Male 15 (65.2%) 9 (69.2%) 1.000
Ethnicity
Asian 8 (34.8%) 0 (0%) 0.044
African American 1 (4.4%) 0 (0%)
Caucasian 5 (21.7%) 7 (43.8%)
Hispanic 6 (26.1%) 8 (50.0%)
Mixed 3 (13.0%) 1 (6.3%)
aReported as means with minimum, maximum, and 95% confidence interval in bracket. T-test was used.
All other variables were reported as the number of patients and were analyzed using Fisher’s Exact test.
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the fragment ions in a tandem mass spectrum. These spec-
tra are matched to database peptide sequences by searching
MS/MS (Mass spectrometry/Mass spectrometry) spectra
against the Swiss-Prot database (version, June 10, 2008)
restricted to human entries (15,720 sequences) using the
SEQUEST search engine. Searches were restricted to 50
and 100 ppm for parent and fragment ions, respectively.
No enzyme restriction was selected. Since we were focusing
on naturally occurring peptides, matches were considered
significant when they were above the statistically significant
threshold (as returned by SEQUEST BioWorks™ rev.3.3.1
SP1). Different fragmentation techniques were used for the
validation of a peptide sequence, as well as for the detec-
tion, localization and characterization of the post-transla-
tional modifications. Due to the strong correlation between
relative protein/peptide abundance and spectral counting
summing all MS/MS spectra observed for the same pep-
tide, the spectral counting method was used to compare
the peptide abundance between KD and FC pooled sam-
ples. If the spectral counting of a peptide differed by two
between KD and FC pooled samples, this peptide was cho-
sen for ABI5800 matrix-assisted laser desorption/ionization
(MALDI) TOF (Time of Flight) confirmation analysis. The
individual peptidomes of 30 KD and 30 FC subjects (Addi-
tional file 1, Supplementary Table 4) were subjected to
liquid chromatography-mass spectrometry (LCMS) based
urine peptide profiling by ABI 5800. We targeted the 139
peptide biomarker candidates revealed by MUDPIT analy-
sis and used their mass to charge ratio (m/z) values of the
ions across all the LC fractions detected to construct
extracted ion chromatograms (XICs) of individual urine
samples. Windows for XIC construction were 25 ppm for
m/z. Peak intensity values were normalized to the mean
intensity of all peaks within a sample and then to the mean
of the individual peptide ions across the samples. To follow
up the potential peptide biomarkers, the statistical signifi-
cance of each peptide’s peak intensity between KD and FC
groups was analyzed using the Mann Whitney U test and
Student’s t test. The urine peptide biomarker panel was
analyzed by supporting vector machine (SVM) algorithm
(R e1071 package). ROC analysis was performed [23,24] to
evaluate the performance of the clinical and molecular-
based classifiers in the diagnosis of KD. Area under the
ROC curve was calculated using RORC package [24].
Sequential predictive analysis integrating clinical and
molecular findings for KD diagnosis
To improve the diagnosis of patients with the intermedi-
ate clinical scores, we used Ensemble Data Mining
Methods, also known as Committee Methods or Model
Combiners [21], to combine the clinical and molecular
biomarker classifiers in order to derive practical algo-
rithms for KD management. These machine learning
methods combine the advantages of multiple models to
achieve better predictive accuracy than is possible with
any individual model [21]. We first stratified subjects
into low, intermediate, and high risk groups based on
clinical scores. Patients with intermediate KD clinical
scores were further analyzed by either blood lymphocyte
expression based or by urine peptidome based classifiers
to improve diagnostic sensitivity and specificity.
Biological pathway analysis
Biological pathway analysis was performed with the
Ingenuity IPA system (Ingenuity Systems, Redwood
City, CA). To identify the canonical pathways that
encompassed our KD biomarkers, 87 genes (94 signifi-
cant probes) revealed by the cell type-specific gene
expression studies of peripheral whole blood samples,
and 13 significant urine peptide markers were mapped
Figure 1 Linear discriminant analysis of KD training cohort patients. (A) The calculated coefficients of linear discriminants (LD1) of each
assayed clinical parameter. (B) A modified 2 × 2 contingency table depicting the agreement of classifications with clinical diagnosis. (C) Density
plots of the clinical score distribution of both the KD and FC patients. KD, blue density plot; FC, yellow density plot. We stratified all the KD and
FC patients, using the clinical scores, into low, intermediate and high groups, where the group boundaries were decided by the diagnosis with
95% accuracy (two dotted vertical lines). Abbreviations: FC, febrile controls; KD, Kawasaki disease.
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to known entries in the IPA canonical pathway database.
The significance of the pathway was tested using Bio-
conductor http://www.bioconductor.org packages as pre-
viously described [25] and pathways with P value < 0.05
were chosen for further analysis.
Results
Development of KD clinical score
A data set of 783 patients, 342 FC and 441 KD, had com-
plete records for 13 clinical and laboratory observations,
which were used for exploratory multivariate linear discri-
minant analysis (LDA) (Tables 1, 2 and 3): number of days
of fever at time of clinical visit (illDay), total white blood
cell (wbc), percentage monocytes (monos), lymphocytes
(lymphs), eosinophils (eos), neutrophils (polys), immature
neutrophils (bands), platelet counts (plts), hemoglobin
(hgb), C-reactive protein (crp), gamma-glutamyl transfer-
ase (ggt), alanine aminotransferase (alt), and erythrocyte
sedimentation rate (ESR). LDA created linear combina-
tions of these clinical variables and calculated coefficients
LD1 to optimize separation between KD and FC groups
(Figure 1A). The discriminant model predicts clinical diag-
nosis with 79.8% overall accuracy (Figure 1B, Fisher exact
test P = 2.2 × 10-16). The seven variables with the largest
absolute values of coefficients LD1 were: days of illness,
concentrations of hemoglobin and C-reactive protein,
white blood cell count, and percentages of eosinophils,
monocytes, and immature neutrophils (Figure 1A) for dis-
criminant score calculation. The LDA discriminant scor-
ing metric, designated as the KD ‘clinical score’, enables
the seven clinical variables to be collectively interpreted on
a scale, rather than a strict binary discrimination. Histo-
grams of KD clinical scores demonstrate the distribution
and considerable overlap of KD and FC patients (Figure
1C). Patients were stratified into three levels of risk for
KD, determined by 95% correct classification effectiveness:
low (clinical score < -1.48; 108 (96%) FC, 5 (4%) KD),
intermediate (-1.481 ≤ clinical score ≤ 1.775, 366 KD and
230 FC) and high (clinical score > 1.775; 70 (95%) KD, 4
(5%) FC) groups. Although the clinical score was accurate
for subjects in the low (n = 113) and high (n = 74) clinical
scoring groups, 596 patients (76%) had intermediate scores
and remained unassigned by our clinical scoring
algorithm.
Cell type-specific significance analysis (csSAM) of
peripheral whole blood expression to differentiate KD
and FC patients
We employed the recently developed csSAM [15]
method, combining our KD array data set (NCBI GEO
GSE15297 [9], blood testing cohort) and patients’ rela-
tive cell type frequencies to analyze differential gene
expression for each blood cell type in KD (n = 23) and
FC (n = 16) subjects’ whole blood. Whole-blood
differential expression analysis using the Significance
Analysis of Microarray (SAM) algorithm [26], revealed
no differentially expressed genes between the KD and
FC groups at a relatively permissive FDR of 0.1 (Figure
2A). For each of the KD and FC patients, we de-convo-
luted the cell type-specific gene expression profile, using
csSAM, to perform cell type-specific differential expres-
sion analysis. Although the whole blood SAM analysis
revealed no significant differentially expressed genes,
and the lymphocyte count itself did not contribute to
the clinical score, the csSAM analysis identified 87 dif-
ferentially (down regulated in KD) expressed genes (94
gene probes; Additional file 1, Supplementary Table 1)
in lymphocytes. Although eosinophil, monocyte and
immature neutrophil relative counts had large LD1 coef-
ficients for the KD clinical score, csSAM analysis identi-
fied no marker genes (FDR < 0.05) for these blood cell
types (Figure 2B). Additional file 1, Supplementary Fig-
ure 1 summarizes the training, 10 fold cross-validation,
and test errors for different values of the threshold,
revealing an effective KD/FC diagnostic gene marker
panel (32 unique genes; top 36 gene probes in Addi-
tional file 1, Supplementary Table 1).
Urine peptidome analysis discriminating KD and FC
patients
As shown in Figure 3, for urine peptidome analyses, we
have employed a combination of methods of multi-
dimensional protein identification technology (MUDPIT:
strong cation exchange SCX and reverse phase RP
separations) analysis using Fourier transform ion cyclo-
tron resonance (FT ICR) to discover candidate biomar-
kers in pooled KD (n = 23) and FC (n = 23) urine
discovering cohort samples. Matrix-assisted laser deso-
rption/ionization (MALDI) mass spectrometric (MS)
TOF analysis was used to confirm these biomarkers in
individual KD (n = 30) and FC (n = 30) urine testing
cohort samples. Our exploratory MUDPIT analysis of
pooled urine peptidomes yielded 139 candidate peptide
biomarkers (Figure 3). Subsequent MALDI TOF analysis
confirmed the statistical significance of 13 urine pep-
tides (Figure 3), which are derived from 9 protein pre-
cursors (collagen type 1 6 alpha 1, collagen type 1 alpha
1, collagen type 3 alpha 1, uromodulin, collagen type 9
alpha 3, collagen type 23 alpha 1, collectin sub-family
member 12, unnamed protein product Q6ZSL6, and
EMI domain containing 1). Sequence alignment of these
peptides revealed tight sequence clusters for the two
COL1A1 and four UMOD peptides.
A novel KD diagnostic algorithm integrating clinical and
molecular biomarker findings
We first computed KD clinical scores for all patients in
the clinical training, blood testing, and urine testing
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cohorts (Figure 4, left panel). Although the clinical score
had high sensitivity (blood: 11 of 11; urine: 5 of 5) and
specificity (blood: 1 of 1; urine: 0 of 2) when limited to
the low and high clinical score groups, the majority of
the blood (27 of 39) and urine (46 of 53) testing cohorts
were in the intermediate group where FC and KD
patients had considerable clinical overlap.
We applied gene expression or urine peptide based
classifiers to better discriminate KD from FC subjects
with intermediate KD clinical scores (Figure 4, middle
panel). The 32-lymphocyte-specific-gene-marker panel
correctly classified 12 of 15 FC and 12 of 12 KD blood
group patients with intermediate clinical scores. The 13-
urine-peptide-biomarker panel correctly classified 18 of
21 FC and 22 of 25 KD urine group patients with inter-
mediate clinical scores. ROC (Figure 4, right panel) ana-
lysis revealed that molecular analyses of blood cell-
specific gene expression (AUC 0.969) and of the urine
peptidome (AUC 0.919) were superior to the clinical
score (AUC 0.810) in differentiating KD from FC
patients with intermediate clinical scores. This analysis
suggests that the integration of clinical and molecular
based panels provides an effective strategy for KD diag-
nosis. Febrile patients with low and high KD clinical
scores are diagnosed with 95% confidence and need no
further evaluation. Additional molecular-based testing,
by either blood array profiling or urine peptidome analy-
sis, refines the diagnostic performance for the remaining
patients with intermediate clinical scores.
Biological pathway analyses of blood lymphocyte-specific
gene markers and urine peptide biomarkers
To characterize the canonical pathways in which our
KD biomarkers are involved, 87 lymphocyte gene mar-
kers (94 significant probes) revealed by the cell type-spe-
cific expression of peripheral whole blood samples, and
13 confirmed urine peptide markers were mapped to
known entries in the IPA (Ingenuity Pathway Analysis)
canonical pathway database (Figure 5). Cellular location
analysis revealed that > 70% of the significant gene pro-
ducts reside within the cytoplasm and nucleus. In con-
trast, as expected, all of the significant urine peptides
Figure 2 Cell type-specific significance analysis of KD and FC whole blood microarray data. (Microarray analysis of peripheral whole
blood, FC n = 16, KD n = 23, Testing data set 1). (A) SAM analysis revealing no differentially expressed genes in whole blood. (B) csSAM
revealing differential expression in lymphocytes, but not in other cell types. Up: up-regulated in FC. Down: down-regulated in FC. Y axis: false
discovery rate (FDR); X axis: number of differential genes at a given FDR. Microarray analysis of peripheral whole blood, FC n = 16, KD n = 23
(Testing data set 1). Abbreviations: FC, febrile controls; KD, Kawasaki disease; SAM, significance analysis of microarrays; scSAM, cell-type specific
significance analysis of microarrays.
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are derived from proteins located either in the extracel-
lular space or on the plasma membrane. Pathway signifi-
cance analysis [25] of blood lymphocyte-specific gene
markers revealed that PI3K signaling (P = 0.003), T cell
receptor signaling (P = 0.005), B cell receptor signaling
(P = 0.02), T helper cell differentiation (P = 0.03) and
natural killer cell signaling (P = 0.04) were significantly
down-regulated in KD compared to FC patients. Urine
peptidome pathway analysis revealed that the intrinsic
prothrombin activation pathway (P = 3.04 × 10-5), hepa-
tic fibrosis/hepatic stellate cell activation (P = 6.49 × 10-
4), dendritic cell maturation (P = 0.001), and IL-6
Figure 3 Urine peptidome analysis. Top panel summarizes the MUDPIT discovery and MALDI MS confirmation processes. Bottom table lists
the 13 confirmed urine peptide biomarker discriminating KD and FC. M/Z: mass to charge ratio. ΔSC: spectral counting difference. Post
translation modifications: * hydroxylation; # methionine oxidation. U Test: P value. Abbreviations: FC, febrile controls; KD, Kawasaki disease; MALDI
MS, Matrix-assisted laser desorption/ionization (MALDI) mass spectrometry; MUDPIT, multi-dimensional protein identification technology.
Figure 4 A sequential predictive algorithm integrating clinical and molecular biomarker findings to improve KD diagnosis. KD, blue; FC
yellow. Left panel: clinical, blood testing, and urine testing cohorts were stratified and ordered according to their clinical scores. Patients with
intermediate scores were further analyzed by 32 gene or 13 urine peptide based classifiers to discriminate KD and FC. Right panel: ROC analysis
of all three-cohort patients with intermediate clinical scores analyzed by either clinical score (black), cell-specific, whole blood gene-based (red)
and urine peptide-based (green) classifiers. Abbreviations: FC, febrile controls; KD, Kawasaki disease; ROC, receiver operating characteristic.
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signaling (P = 0.01) were significantly down-regulated in
KD compared to FC.
Discussion
We have identified three different biomarker panels (7
clinical parameters, 32 blood lymphocyte-specific genes,
13 urine peptides) and developed an integrated algo-
rithm to accurately diagnose KD.
The clinical data we used in the multivariate analysis are
routinely obtained during the evaluation of fever. How-
ever, clinicians have not used scoring systems derived by
multivariate techniques for KD diagnosis. Although the
clinical score correctly classified only 80% of febrile
patients, patients with either low or high KD clinical
scores were diagnosed as FC or KD respectively with 95%
accuracy. For febrile patients with the confident diagnosis
of KD, timely administration of IVIG can thus be feasible
to prevent the development of coronary artery dilatation
or aneurysms. For febrile patients with intermediate clini-
cal scores for whom confident diagnosis is not feasible, we
developed a sequential algorithm, integrating clinical and
molecular findings to improve KD diagnosis. Both the per-
ipheral blood cell type-specific analysis and the urine pep-
tidome biomarker analysis yielded sensitive and specific
classifiers, which performed well in the diagnosis of KD.
Prospective testing of these biomarker panels will be
necessary to confirm their diagnostic utilities.
The csSAM-derived lymphocyte-specific gene markers
and their mapped canonical pathways, for example PI3K
signaling in B cells and T cell receptor signaling, provide
insight into the host response in KD. Confirmation of
our de-convolution observations on independent sam-
ples will establish the role of these genes as KD biomar-
kers. Validation of these markers may help to focus the
search for the etiology of KD on agents that suppress
specific lymphocyte gene expression.
Figure 5 Pathway analysis of the lymphocte-specific gene (A) or urine peptide (B) markers. Data mining software (Ingenuity Systems,
http://www.ingenuity.com, Redwood City, CA) was used with differentially (KD vs FC) expressed genes or peptides to identify gene ontology
groups and relevant canonical signaling pathways. The intensity of the node color indicates the degree of up- (red) or down- (green) regulation
in KD. Nodes are displayed using shapes that represent the functional classes of the gene products, and different line types represent various
relationships. Relationships are primarily due to co-expression. Abbreviations: FC, febrile controls; KD, Kawasaki disease.
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The overlapping sequences of the two COL1A1 and
four UMOD peptides suggests that these peptide bio-
markers reflect differential activities of disease-related
proteases or their inhibitors such as TIMP1 or matrix
metalloproteinases in KD [6,27-32]. Serum peptide bio-
marker analysis of cancer subjects [33] has demon-
strated overlapping peptide biomarkers generated by
disease-specific exo-peptidase activity. We have also
observed tight clusters of urine peptide biomarkers in
renal allograft dysfunction [19] and SJIA [19]. Therefore,
the discovery of multiple overlapping collagen and uro-
modulin peptides suggests that the pathophysiology of
KD involves the active degradation of proteins including
collagen and uromodulin.
With respect to the concern regarding incomplete KD
cases hidden among the FC, we agree that inaccurate
diagnosis is always one of the limitations in the absence
of a gold standard diagnostic test. However, FC in this
study included only patients whose illness resolved
within three days of blood sampling OR for whom a
definite diagnosis was established (for example osteo-
myelitis, JIA). None of the FC included here had peeling
in the convalescent phase. As for the KD patients, we
have maintained a stable rate of coronary artery aneur-
ysms from year to year (approximately 9%) suggesting
that our diagnostic practices are stable. All the KD
patients in this study were evaluated by one of two
experienced clinicians at a single medical center. In this
study, most of the FCs were enrolled by our team mem-
ber, thus assuring consistency in diagnosis and sample
collection. Our study is unique in focusing on a clini-
cally relevant control group of children with fever who
were actually being evaluated to rule in or rule out KD.
All FC were evaluated with a standardized set of clinical
laboratory tests that was also used to evaluate our KD
patients. Our study also differs from many previous
investigations on KD that used samples collected from a
large number of hospitals that cared for only a few KD
patients each. Therefore, a big problem with consistency
in these studies was expected for comparative studies
between KD and FC.
Although all FC subjects in this study had laboratory
testing for KD as recommended by the American Heart
Association (AHA), very few FC had echocardiographic
studies done. This is indeed a limitation. Although we
acknowledge the potential inaccurate diagnosis of
incomplete KD, our status as the sole freestanding chil-
dren’s hospital, sole KD referral center, and sole pedia-
tric emergency department in San Diego County
(catchment area of 5 million people) maximizes the like-
lihood that FC with persistent or progressive illness con-
fused with KD would be captured during a return visit.
We recognize several limitations to the current mole-
cular study for future translations of these biomarkers
into bedside practice. First, the small sample sizes limit
the power of our biomarker analyses to validate statisti-
cally significant associations and to avoid spurious dis-
covery. Future prospective studies with larger sample
sizes will be needed to validate our cell type-specific
gene expression and urine peptide biomarkers. A second
limitation of our study was the lack of formal assess-
ment by clinicians of the pre-test probability of KD in
the subjects included in this study. While a large pro-
portion of the febrile controls were referred to our
emergency department by physicians for evaluation of
possible KD, this was not uniformly true as some febrile
controls likely had a low pre-test probability of KD.
Since the pre-test probability is an important considera-
tion in evaluating the performance of a diagnostic test,
collection of this information will be critical in the next
testing phase of a KD diagnostic test. Third, the applica-
tion of both the cell-specific transcript patterns and
urine peptide biomarkers for the diagnosis of KD will
require development of technology for the rapid identifi-
cation of both whole blood transcripts and urine protein
fragments in the clinical laboratory.
Our flexible clinical scoring metric is amenable to
automation to develop data-driven predictive systems.
Consistent with the current mandate to improve elec-
tronic medical record (EMR) use [34] and future inter-
operability between the hospital EMR and our
predictive algorithm based applications consisting of
demographic, clinical and genomic/proteomic data can
serve an effective platform to allow interfacing between
interdisciplinary teams (bed and bench side; what is
known and what is practiced) for productive transla-
tional medicine.
Conclusion
To the best of our knowledge, this is the first report
describing a method integrating both clinical and mole-
cular findings to discriminate KD from FC. Subsequent
testing feedback from prospective KD/FC EMR data can
be expected to further refine the clinical scoring metric
and improve the KD diagnosis [34].
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